News 
Market Data 
Discover
Replies to post #149397 on Anavex Life Sciences Corp (AVXL)
Big pharma greets hundreds of ex-federal workers at the 'revolving door'
By Sydney Lupkin | January 25, 2018
Alex Azar's job hop from drugmaker Eli Lilly and Co. to the Trump administration reflects ever-deepening ties between the pharmaceutical industry and the federal government.
A Kaiser Health News analysis shows that hundreds of people have glided through the "revolving door" that connects the drug industry to Capitol Hill and the Department of Health and Human Services.
Azar was confirmed Wednesday as HHS secretary, joining other former drug industry alumni in top positions.
Nearly 340 former congressional staffers now work for pharmaceutical companies or their lobbying firms, according to data analyzed by KHN and provided by Legistorm, a nonpartisan congressional research company. On the flip side, the analysis showed, more than a dozen former drug industry employees now have jobs on Capitol Hill — often on committees that handle health care policy.
"Who do they really work for?" said Jock Friedly, Legistorm's president and founder, who called that quantity "substantial." "Are they working for the person who is paying their bills at that moment or are they essentially working on behalf of the interests who have funded them in the past and may fund them in the future?"
AI
